Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2005;97:e60-e70
Published online before print August 18, 2005, doi: 10.1161/01.RES.0000182631.33638.77
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
97/6/e60    most recent
01.RES.0000182631.33638.77v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mould, A. W.
Right arrow Articles by Kay, G. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mould, A. W.
Right arrow Articles by Kay, G. F.
Related Collections
Right arrow Angiogenesis
Right arrow Genetically altered mice
Right arrow Growth factors/cytokines
(Circulation Research. 2005;97:e60.)
© 2005 American Heart Association, Inc.


UltraRapid Communication

Transgenic Overexpression of Vascular Endothelial Growth Factor-B Isoforms by Endothelial Cells Potentiates Postnatal Vessel Growth In Vivo and In Vitro

Arne W. Mould, Sonia A. Greco, Marian M. Cahill, Ian D. Tonks, Daniela Bellomo, Carol Patterson, Anna Zournazi, Andrew Nash, Pierre Scotney, Nicholas K. Hayward, Graham F. Kay

From the Queensland Institute of Medical Research (A.W.M., S.A.G., M.M.C., I.D.T., D.B., C.P., A.Z., N.K.H., G.F.K.), Herston, Brisbane, Queensland; and AMRAD Corp Ltd (A.N., P.S.), Richmond, Victoria, Australia.

Correspondence to Dr Arne Mould, Queensland Institute of Medical Research, Cancer and Cell Biology Division, Post Office Royal Brisbane Hospital, Brisbane, QLD 4029, Australia. E-mail arneM{at}qimr.edu.au

Vascular endothelial growth factors (VEGFs) play significant roles in endothelial growth, survival, and function, and their potential use as therapeutic agents to promote the revascularization of ischemic tissues in being avidly explored. VEGF-A has received most attention, as it is a potent stimulator of vascular growth. Results in clinical trials of VEGF-A as a therapeutic agent have fallen short of high expectations because of serious edematous side effects caused by its activity in promoting vascular permeability. VEGF-B, a related factor, binds some of the VEGF-A receptors but not to VEGF receptor 2, which is implicated in the vascular permeability promoting activity of VEGF-A. Despite little in vitro evidence to date for the ability of Vegf-B to directly promote angiogenesis, recent data indicate that it may promote postnatal vascular growth in mice, suggesting that it may have potential therapeutic application. We have specifically studied the effects of VEGF-B on vascular growth in vivo and on angiogenesis in vitro by analyzing transgenic mice in which individual isoforms (VEGFB167Tg and VEGFB186Tg) of VEGF-B are overexpressed in endothelial cells. VEGFB167Tg and VEGFB186Tg mice displayed enhanced vascular growth in the Matrigel assay in vivo and during cutaneous wound healing. In the aortic explant assay, explants from VEGFB167Tg and VEGFB186Tg mice displayed elevated vascular growth, suggesting a direct effect of VEGF-B isoforms in potentiating angiogenesis. These data support the use of VEGF-B as a therapeutic agent to promote vascular growth, in part, by potentiating angiogenesis. Furthermore, the lack of vascular permeability activity associated with either transgenic overexpression of the VEGF-B gene in endothelial cells or application of VEGF-B protein to the skin of mice in the Miles assay indicates that use of VEGF-B as a therapy should not be associated with edematous side effects.


Key Words: vascular endothelial growth factor-B • growth factor • angiogenesis • endothelium




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
F. Zhang, Z. Tang, X. Hou, J. Lennartsson, Y. Li, A. W. Koch, P. Scotney, C. Lee, P. Arjunan, L. Dong, et al.
VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis
PNAS, April 14, 2009; 106(15): 6152 - 6157.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
C. Ruiz de Almodovar, D. Lambrechts, M. Mazzone, and P. Carmeliet
Role and Therapeutic Potential of VEGF in the Nervous System
Physiol Rev, April 1, 2009; 89(2): 607 - 648.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
W. Schaper
The Renaissance of Vascular Endothelial Growth Factor, Part B
Circ. Res., October 24, 2008; 103(9): 903 - 904.
[Full Text] [PDF]


Home page
Circ. Res.Home page
T. Karpanen, M. Bry, H. M. Ollila, T. Seppanen-Laakso, E. Liimatta, H. Leskinen, R. Kivela, T. Helkamaa, M. Merentie, M. Jeltsch, et al.
Overexpression of Vascular Endothelial Growth Factor-B in Mouse Heart Alters Cardiac Lipid Metabolism and Induces Myocardial Hypertrophy
Circ. Res., October 24, 2008; 103(9): 1018 - 1026.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
X. Li, M. Tjwa, I. Van Hove, B. Enholm, E. Neven, K. Paavonen, M. Jeltsch, T. D. Juan, R. E. Sievers, E. Chorianopoulos, et al.
Reevaluation of the Role of VEGF-B Suggests a Restricted Role in the Revascularization of the Ischemic Myocardium
Arterioscler Thromb Vasc Biol, September 1, 2008; 28(9): 1614 - 1620.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
A. W. Mould, P. Scotney, S. A. Greco, N. K. Hayward, A. Nash, and G. F. Kay
Prophylactic but not therapeutic activity of a monoclonal antibody that neutralizes the binding of VEGF-B to VEGFR-1 in a murine collagen-induced arthritis model
Rheumatology, March 1, 2008; 47(3): 263 - 266.
[Abstract] [Full Text] [PDF]